

[Protamine sulfate](#)

Essential medicine status

Section:

[10. Medicines affecting the blood](#) [10.2. Medicines affecting coagulation](#)

ATC codes: [V03AB14](#)

EMLc

Indication

Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors ICD11 code: [3B21](#)

INN

Protamine sulfate

Medicine type

Chemical agent

List type

Core (EML)

Complementary (EMLc)

Formulations

Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1984 ([TRS 722](#))

Changed in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Protamine sulfate](#)

DrugBank

[Protamine sulfate](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.